GRHL2 Acts As an Anti-Oncogene in Bladder Cancer by Regulating ZEB1 in Epithelial-Mesenchymal Transition (EMT) Process [Erratum]
Total Page:16
File Type:pdf, Size:1020Kb
OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ERRATUM GRHL2 Acts as an Anti-Oncogene in Bladder Cancer by Regulating ZEB1 in Epithelial-Mesenchymal Transition (EMT) Process [Erratum] Shen J, Lv X, Zhang L. Onco Targets Ther. 2020;13:2511– 2522. The authors have advised the cities are missing from the affiliation list on page 2511. This error was introduced by the Editorial staff during the publication process. The correct author list and affiliations are as follows. Jingang Shen1,* Xianbao Lv1,* Lei Zhang2 1Department of Urology, Chengwu County People’s Hospital, Heze City, Shandong 274200, People’s Republic of China; 2Department of Urology, Zoucheng People’s Hospital, Jining City, Shandong 273500, People’s Republic of China *These authors contributed equally to this work OncoTargets and Therapy Dovepress Publish your work in this journal OncoTargets and Therapy is an international, peer-reviewed, open agents and protocols on patient perspectives such as quality of life, access journal focusing on the pathological basis of all cancers, adherence and satisfaction. The manuscript management system is potential targets for therapy and treatment protocols employed to completely online and includes a very quick and fair peer-review improve the management of cancer patients. The journal also system, which is all easy to use. Visit http://www.dovepress.com/ focuses on the impact of management programs and new therapeutic testimonials.php to read real quotes from published authors. Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal submit your manuscript | www.dovepress.com OncoTargets and Therapy 2020:13 10759 10759 DovePress © 2020 Shen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php http://doi.org/10.2147/OTT.S283751 and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)..